562 related articles for article (PubMed ID: 32266056)
1. Roles of the PI3K/AKT/mTOR signalling pathways in neurodegenerative diseases and tumours.
Xu F; Na L; Li Y; Chen L
Cell Biosci; 2020; 10(1):54. PubMed ID: 32266056
[TBL] [Abstract][Full Text] [Related]
2. Xihuang pills induce apoptosis in hepatocellular carcinoma by suppressing phosphoinositide 3-kinase/protein kinase-B/mechanistic target of rapamycin pathway.
Teng YJ; Deng Z; Ouyang ZG; Zhou Q; Mei S; Fan XX; Wu YR; Long HP; Fang LY; Yin DL; Zhang BY; Guo YM; Zhu WH; Huang Z; Zheng P; Ning DM; Tian XF
World J Gastrointest Oncol; 2022 Apr; 14(4):872-886. PubMed ID: 35582102
[TBL] [Abstract][Full Text] [Related]
3. Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer.
Lim HJ; Crowe P; Yang JL
J Cancer Res Clin Oncol; 2015 Apr; 141(4):671-89. PubMed ID: 25146530
[TBL] [Abstract][Full Text] [Related]
4. PI3K/AKT/mTOR signalling pathway involvement in renal cell carcinoma pathogenesis (Review).
Miricescu D; Balan DG; Tulin A; Stiru O; Vacaroiu IA; Mihai DA; Popa CC; Papacocea RI; Enyedi M; Sorin NA; Vatachki G; Georgescu DE; Nica AE; Stefani C
Exp Ther Med; 2021 May; 21(5):540. PubMed ID: 33815613
[TBL] [Abstract][Full Text] [Related]
5. PI3K/Akt/mTOR Signaling Pathway in Blood Malignancies-New Therapeutic Possibilities.
Wiese W; Barczuk J; Racinska O; Siwecka N; Rozpedek-Kaminska W; Slupianek A; Sierpinski R; Majsterek I
Cancers (Basel); 2023 Nov; 15(21):. PubMed ID: 37958470
[TBL] [Abstract][Full Text] [Related]
6. Activation of PI3K/Akt/mTOR pathway and dual inhibitors of PI3K and mTOR in endometrial cancer.
Chen J; Zhao KN; Li R; Shao R; Chen C
Curr Med Chem; 2014; 21(26):3070-80. PubMed ID: 24735369
[TBL] [Abstract][Full Text] [Related]
7. Tormentic acid inhibits hepatic stellate cells activation via blocking PI3K/Akt/mTOR and NF-κB signalling pathways.
Lin X; Li Y; Zhang X; Wei Y; Wen S; Lu Z; Huang Q; Wei J
Cell Biochem Funct; 2021 Jan; 39(1):77-87. PubMed ID: 32564421
[TBL] [Abstract][Full Text] [Related]
8. PI3K/Akt/mTOR Signaling Pathway: Role in Esophageal Squamous Cell Carcinoma, Regulatory Mechanisms and Opportunities for Targeted Therapy.
Luo Q; Du R; Liu W; Huang G; Dong Z; Li X
Front Oncol; 2022; 12():852383. PubMed ID: 35392233
[TBL] [Abstract][Full Text] [Related]
9. The PI3K/AKT/mTOR signalling pathway is active in salivary gland cancer and implies different functions and prognoses depending on cell localisation.
Ettl T; Schwarz-Furlan S; Haubner F; Müller S; Zenk J; Gosau M; Reichert TE; Zeitler K
Oral Oncol; 2012 Sep; 48(9):822-30. PubMed ID: 22445095
[TBL] [Abstract][Full Text] [Related]
10. Targeting Abnormal PI3K/AKT/mTOR Signaling in Intracerebral Hemorrhage: A Systematic Review on Potential Drug Targets and Influences of Signaling Modulators on Other Neurological Disorders.
Jadaun KS; Sharma A; Siddiqui EM; Mehan S
Curr Rev Clin Exp Pharmacol; 2022; 17(3):174-191. PubMed ID: 34455956
[TBL] [Abstract][Full Text] [Related]
11. Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer.
Yu L; Wei J; Liu P
Semin Cancer Biol; 2022 Oct; 85():69-94. PubMed ID: 34175443
[TBL] [Abstract][Full Text] [Related]
12. Analysis of PI3K/AKT/mTOR signalling pathway in high risk neuroblastic tumours.
Iżycka-Świeszewska E; Drożyńska E; Rzepko R; Kobierska-Gulida G; Grajkowska W; Perek D; Balcerska A
Pol J Pathol; 2010; 61(4):192-8. PubMed ID: 21290341
[TBL] [Abstract][Full Text] [Related]
13. Small biomarkers with massive impacts: PI3K/AKT/mTOR signalling and microRNA crosstalk regulate nasopharyngeal carcinoma.
Li HL; Deng NH; He XS; Li YH
Biomark Res; 2022 Jul; 10(1):52. PubMed ID: 35883139
[TBL] [Abstract][Full Text] [Related]
14. Effect of Glut-1 and HIF-1α double knockout by CRISPR/CAS9 on radiosensitivity in laryngeal carcinoma via the PI3K/Akt/mTOR pathway.
Bao YY; Zhong JT; Shen LF; Dai LB; Zhou SH; Fan J; Yao HT; Lu ZJ
J Cell Mol Med; 2022 May; 26(10):2881-2894. PubMed ID: 35415942
[TBL] [Abstract][Full Text] [Related]
15. PI3K/ Akt/ mTOR Pathway as a Therapeutic Target for Colorectal Cancer: A Review of Preclinical and Clinical Evidence.
Narayanankutty A
Curr Drug Targets; 2019; 20(12):1217-1226. PubMed ID: 31215384
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of PI3K/AKT/mTOR pathway inhibitors for the treatment of advanced solid cancers: A literature-based meta-analysis of 46 randomised control trials.
Li X; Dai D; Chen B; Tang H; Xie X; Wei W
PLoS One; 2018; 13(2):e0192464. PubMed ID: 29408858
[TBL] [Abstract][Full Text] [Related]
17. High Sensitivity of Circulating Tumor Cells Derived from a Colorectal Cancer Patient for Dual Inhibition with AKT and mTOR Inhibitors.
Smit DJ; Cayrefourcq L; Haider MT; Hinz N; Pantel K; Alix-Panabières C; Jücker M
Cells; 2020 Sep; 9(9):. PubMed ID: 32962206
[TBL] [Abstract][Full Text] [Related]
18. Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma.
Beck JT; Ismail A; Tolomeo C
Cancer Treat Rev; 2014 Sep; 40(8):980-9. PubMed ID: 25037117
[TBL] [Abstract][Full Text] [Related]
19. Recent Advances in Dual PI3K/mTOR Inhibitors for Tumour Treatment.
Wu X; Xu Y; Liang Q; Yang X; Huang J; Wang J; Zhang H; Shi J
Front Pharmacol; 2022; 13():875372. PubMed ID: 35614940
[TBL] [Abstract][Full Text] [Related]
20. Alpha1-ACT Functions as a Tumour Suppressor in Hepatocellular Carcinoma by Inhibiting the PI3K/AKT/mTOR Signalling Pathway via Activation of PTEN.
Zhu H; Liu Q; Tang J; Xie Y; Xu X; Huang R; Zhang Y; Jin K; Sun B
Cell Physiol Biochem; 2017; 41(6):2289-2306. PubMed ID: 28456796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
